Key result
Oral anticoagulant-specific reversal agents, including idarucizumab, andexanet alfa, and ciraparantag, provide rapid reversal of anticoagulant activity without apparent thromboembolic concerns.
Design
Review
Authors
Loading...
May inform institutional reversal protocols; leaves open need for randomized safety confirmation.
Specific reversal agents for direct oral anticoagulants provide rapid reversal of anticoagulant activity, requiring advance planning and protocol development by pharmacy departments.
Smythe et al. (2016) conducted a review in Anticoagulation reversal. Oral anticoagulant-specific reversal agents (idarucizumab, andexanet alfa, ciraparantag) was evaluated. Oral anticoagulant-specific reversal agents, including idarucizumab, andexanet alfa, and ciraparantag, provide rapid reversal of anticoagulant activity without apparent thromboembolic concerns.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: